The U.S. spends $15,474 per person on healthcare annually, nearly double the next highest-spending wealthy nation and roughly triple the average across developed countries. That gap isn’t because Americans use more healthcare. They visit doctors less often and spend fewer days in hospitals than people in most peer nations. The difference comes down to price: every piece of the system, from a single pill to a single bill, costs more in the U.S. than virtually anywhere else.
Higher Prices, Not More Care
The simplest explanation is also the most important one. Americans don’t consume unusually large amounts of healthcare. They see fewer doctors per year than people in Germany or France, and hospital stays are shorter. What drives spending is that each individual service carries a dramatically higher price tag.
A coronary artery bypass surgery billed through a private U.S. insurer costs roughly $89,000. The same procedure in France costs about $12,500 through public insurance. Even through Medicare, the U.S. price sits around $44,000. An outpatient MRI of a leg joint costs $566 through a private plan in the U.S., compared to $58 in France. These aren’t cherry-picked outliers. Across nearly every category of care, from routine imaging to complex surgery, prices in the U.S. run several times higher than in other wealthy countries.
The gap is even wider than those numbers suggest. Medicare price estimates for the U.S. exclude physician fees, meaning the real cost difference between American and international prices is likely understated in most comparisons.
Prescription Drugs Cost Nearly Three Times More
Drug pricing is one of the most visible cost drivers. In 2022, U.S. prices across all prescription drugs were 2.78 times as high as prices in comparable countries. For brand-name drugs specifically, U.S. prices were at least 3.22 times higher, even after accounting for the rebates that manufacturers pay back to insurers.
Most other wealthy countries negotiate drug prices at a national level or set price ceilings. A government agency evaluates whether a drug is worth its asking price, and manufacturers either accept a lower price or lose access to the entire national market. The U.S. has historically lacked this kind of centralized bargaining power. Drugmakers set their own prices and negotiate separately with each insurer, pharmacy benefit manager, and hospital system. The result is that Americans often pay several times more for the exact same medication available for less across the border in Canada or across the Atlantic in Europe.
Administrative Costs Dwarf Other Nations
Between 15 and 30 percent of all U.S. healthcare spending goes to administration, not to treating patients. The U.S. spends $1,055 per person on administrative costs alone. Germany, the next highest spender among wealthy nations, spends $306 per person. That gap reflects a uniquely fragmented system: hundreds of private insurers, each with different coverage rules, billing codes, prior authorization requirements, and claims processes.
This complexity hits at the level of individual bills. Processing a single inpatient bill in the U.S. costs more than $172, compared to $50 in Australia and about $16 in the Netherlands. Every hospital, clinic, and doctor’s office needs staff dedicated to coding, billing, submitting claims, appealing denials, and following up on payments across multiple payers. A single-payer system or a system with standardized billing rules (as most other countries use) eliminates much of this overhead. In the U.S., it’s baked into the price of every visit.
For physicians specifically, this burden translates into hours spent on paperwork rather than patient care. Doctors and their staff navigate insurance verification, prior authorizations, and documentation requirements that simply don’t exist in the same form elsewhere. All of that labor costs money, and it shows up in higher bills.
Fee-for-Service Rewards Volume Over Value
The dominant payment model in U.S. healthcare pays providers for each visit, test, and procedure they perform. This is called fee-for-service, and it creates a straightforward financial incentive: do more, bill more. There is no built-in reward for keeping patients healthy, coordinating care efficiently, or avoiding unnecessary procedures.
The Commonwealth Fund has identified this model as a root cause of fragmented care, variable quality, and rapidly growing costs. Fee-for-service actively discourages the kind of coordination that keeps spending in check. When a primary care doctor, a specialist, a lab, and a hospital are each paid separately for each thing they do, nobody has a financial reason to step back and ask whether all of those services are necessary. In countries that pay doctors a salary or use bundled payments (a single fee covering an entire episode of care), there’s less incentive to order the extra scan or schedule the follow-up visit that doesn’t change the treatment plan.
Defensive Medicine Adds Billions
The U.S. malpractice environment pushes doctors to order tests and procedures that are medically marginal but legally protective. This practice, known as defensive medicine, costs an estimated $50 billion per year. An extra CT scan, a referral to a specialist “just in case,” a blood panel that won’t change the diagnosis: these add up across millions of patient encounters. Other countries with less litigious medical cultures and different liability structures don’t face the same pressure, which keeps their per-visit costs lower.
Private Insurance Inflates Prices
In most peer nations, a single government payer or a small number of heavily regulated insurers negotiate prices with hospitals and doctors. That gives the payer enormous leverage. In the U.S., the market is split among hundreds of private insurers, each negotiating separately with provider networks. Hospitals and health systems that dominate a region can demand high prices because insurers can’t afford to exclude them from their networks. The result is that privately insured patients pay dramatically more than those on public insurance for identical care.
The bypass surgery comparison illustrates this clearly. Through Medicare, the procedure costs about $44,000. Through a private insurer, it’s $89,000, more than double, for the same operation at the same hospital. That spread between public and private prices is far wider in the U.S. than in countries like Australia, where private plans actually pay less than public insurance for the same surgery.
All This Spending Doesn’t Buy Better Health
If the U.S. were getting superior results for all this money, the spending might make sense. It isn’t. Americans have a lower life expectancy than people in most other wealthy nations. Maternal mortality is significantly higher. Rates of chronic disease, infant mortality, and preventable death all lag behind countries that spend a fraction of what the U.S. does.
The spending goes to higher prices, higher administrative overhead, and a payment system that rewards volume. It does not translate into more access (tens of millions of Americans remain uninsured or underinsured), more preventive care, or longer lives. Countries like France, Australia, Germany, and the U.K. cover their entire populations, spend far less per person, and consistently achieve better health outcomes on nearly every measure that matters.
Healthcare in the U.S. costs what it does not because of a single broken piece, but because every piece of the system, from the price of a pill to the cost of processing a bill, operates at a premium that exists nowhere else in the world. The total, $5.3 trillion in 2024 alone, now accounts for 18% of the entire U.S. economy.